Brainsway Ltd. has announced a strategic collaboration with Mindful Health Solutions (MHS) aimed at expanding patient access to innovative mental health treatments. This partnership is significant as it reflects Brainsway's commitment to enhancing interventional psychiatry and improving patient outcomes through advanced neurostimulation technologies.

Founded in 2003, Brainsway is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company operates under the SIC classification of Surgical & Medical Instruments & Apparatus. Recently, it has been active in the market, filing several reports, including a 6-K on October 26, 2026, and another 6-K on November 2, 2026, which details this latest collaboration.

The filing reveals that the collaboration with MHS aims to enhance access to Brainsway's Deep TMS™ and the recently FDA-cleared accelerated SWIFT™ treatment protocol. Additionally, the companies plan to explore integrating Neurolief’s Proliv™Rx at-home neuromodulation therapy into broader patient care pathways. This initiative is expected to facilitate physician education and clinical awareness through joint programs and research.

“We are elated to collaborate with Mindful Health Solutions, an organization that shares our commitment to advancing interventional psychiatry,” said Hadar Levy, Chief Executive Officer of Brainsway. This partnership is expected to deepen the relationship between Brainsway and one of the leaders in brain medicine research and clinical operations in the U.S.

The collaboration comes at a time when Brainsway is also making strides in its broader strategic initiatives, including a recent follow-on equity investment of $0.8 million in the management services organization servicing the Texas-based “Heading Health” clinic network. This indicates a proactive approach by Brainsway to partner with leading behavioral health providers to increase awareness and accelerate the growth of interventional psychiatry.

The strategic collaboration may affect various stakeholders, including healthcare providers, patients seeking mental health treatments, and competitors in the surgical and medical instruments sector. As Brainsway and MHS work together, they may set a precedent for similar partnerships in the industry, potentially influencing how mental health services are delivered.

Details were not available in the SEC filing regarding what happens next following this announcement. However, the collaboration is expected to enhance Brainsway's market position and improve access to its innovative treatment options.